Abstract
In Reply.— We would like to clarify some issues raised by the letter of Dr Kufs. Regarding the dose of the β-agonist used to treat the patients, this was not an arbitrary choice but rather part of an experimental protocol in which all patients were treated in a uniform manner to minimize variables in the study. Metaproterenol and albuterol were used, and all patients received two aerosolized treatments within the first 90 minutes prior to entry into the protocol. Only the patients with initial peak expiratory flow rates less than 200 L/min who failed to double this value by 90 minutes were entered into the study. The design of our study evaluated the bronchodilator activity of magnesium sulfate in a subgroup of asthmatic patients who were severely obstructed and for whom adjunct therapy would be a welcome addition to our therapeutic armamentarium. It would have been possible to adjust the
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
